Return to Today's science sparks archives
Click the tweet icon above each article title to share it on Twitter.
|
Fig 1. Exercise-induced protection against tissue-specific perturbations in organs involved in cancer regulation or prone to malignancy.
|
|
|
Fig. 4: Cytogenetic and molecular features of locally advanced/metastatic mucinous tubular and spindle cell carcinoma.
|
|
|
Fig. 1. Patterns of pan-Trk immunohistochemistry expression in NTRK fusion positive cancers.
|
|
|
Fig. 2. Computational strategy and description of driver co-occurrence (DCO) networks.
|
 |
|
Fig. 2. p53 immunohistochemical expression patterns and correlation with TP53 mutation status in high grade urothelial carcinoma of the bladder.
|
|
|
Fig. 1. Morphologic spectrum of SMARCB1-deficient SNCs.
|
|
|
Fig. 1. The origins of clonal hematopoiesis (CH) detected in allogeneic hematopoietic cell transplantation (allo-HCT) recipients post-transplant.
|
|
|
Figure 1: Examples of CD19 (a) and CD40 (b)‐dependent gating are shown.
|
|
|
Figure 1: Services provided by our lay navigation staff, which encompassed managing medical and treatment, financial, and psychosocial barriers to the timely completion of treatment.
|
|
|
Fig 1..Scheme for chemotherapy induced ceramide-rich microdomains (CRM = CRP ceramide-rich platforms) generation.
|
|
|
Fig 1. The American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading and recommended management for cytokine release syndrome (CRS) and neurological toxicity associated with immune effector cells (ICANS). DXM, Dexamethasone; ICE, immune effector cell-associated encephalopathy; ICU, intensive care unit; MP, Methylprednisolone.
|
|
|
Figure 2. Schematic capturing our current general approach for relapsed or refractory patients with AML with some factors guiding the clinical decision process.
|
|
|
Fig 4. MSI proteins in hippocampus and cortex of P301L tau mouse model.
|
|
|
Fig 4. Pairs of features in predictive models.
|
|
|
Fig 2. CRISPR/Cas9 mediated gene editing.
|
|
|
Visual Abstract
|
|
|
FIGURE 5. Changes in knowledge.
|
|
|
Fig 1. An active IDO/TDO-Kyn-AHR pathway associates with immune suppressive features in human cancers.
|
|
|
Fig 2. TXNIP suppression is PGD-dependent.
|
|
|
Fig. 2. Histologic features of resection specimen.
|
|
|
Fig 2. Suggested infection prevention practices for bone marrow transplant units.
|
|
|
Figure 8. Two components of DNA replication-dependent LexA cleavage.
|
|
|
Graphical Abstract
|
|
|
Fig. 1. Histopathology: clear cell RCC.
|
|
|
Fig 1. Schematic of the five levels of epigenomics that drive transcriptional programmes in sarcomas.
|
|
|
Figure 1. Which ED patients benefit from the palliative approach?
|
|
|
Graphical Abstract.
|
|
|
Fig. 2. Immunohistochemical analysis of complement deposition in normal-appearing deltoid skin biopsies of three severe COVID-19 patients.
|
|
|
FIGURE 3.True-negative and false-positive PLG.
|
|
|
Figure: Correlations Between City Variables and Parking Costs
|
|
|
Graphical Abstract
|
|
|
Fig. 1. Best change in tumor size and characteristics in RECIST efficacy evaluable patients (N = 12).
|
|
|
Figure 1 COVID‐19 infection and immunotherapy for individual patients.
|
|
|
Fig 6. SOAT1 abrogates cholesterol feedback inhibition to promote mevalonate pathway dependency in PDAC.
|
|
|
Figure 1. TET2KO Cells Are More Stem-like than TET2WT Isogenic Counterparts.
|
|
|
Fig 2. Chest CT demonstrates a right lower lobe mass with central low attenuation consistent with necrosis, a feature significantly associated with decreased out-of-field failure.
|
|
|
Graphical Abstract
|
|
|
Graphical Abstract
|
|
|
Fig 2. Heatmap of candidate gene expressions with hierarchical clustering in PTCs (RPTECs) exposed to 6 different FLCs (T-κ1, T-κ2, T-κ3, T-λ1, T-λ2, T-λ3) for 24 hours.
|
|
|
Fig 2. Various routes to leukemic transformation in MPNs.
|
|
|
Fig 1. Incorporating telehealth and COVID‐19 precautions into cancer care during the pandemic: preflight checklist.
|
|
|
Figure 2. Progression-free survival.
|
|
|
Fig. 4 Increased Activation of Intratumoral CD8+ T cells in Patients Treated with Pegilodecakin.
|
|
|
Fig. 1 Sparse CSF iron promotes LCN2 expression in cancer cells.
|
|
|
Fig. 2: Patient cohort and samples.
|
|
|
Figure 1. Analysis of AR-FL and AR-Vs in prostate tissue (A-C) and CRPC blood samples (D-F).
|
|
|
Fig 2. ROC and precision-recall curves for the best models
|
|
|
Fig. 1 Maximum severity (A) and reversibility (B) of treatment-emergent adverse events (AEs) leading to permanent discontinuation.
|
|
|
Graphical Abstract
|
|
|
Figure 1. Germline mutations in patients with Lynch syndrome.
|
|
|
Fig. 2: Low-dose AET inhibits migration of monocytic MDSCs from the bone marrow to the lung premetastatic microenvironment by downregulating expression of CCR2.
|
|
|
Fig. 1. Biodistribution of [225Ac]hu11B6.
|
|
|
Graphical Abstract.
|
|
|
Figure 3.Favorable response to repotrectinib in ROS1-TKI treatment-naïve and ceritinib-resistant patients.
|
|
|
Figure 2. Fraction genome altered, the proportion of genes with copy number alterations and a consequence of genomic instability, is compared by clinical phenotypes (with unadjusted mean group difference and 95% CI).
|
|
|
Figure 1 Swimmer plot of patients with mUM treated with ipilimumab +nivolumab.
|
|
|
Figure 1. COVID-19 in patients with lung cancers.
|
|
|
Figure 3. Allogeneic T cells induce cell death in intestinal organoids with autophagy gene mutations.
|
|
|
Figure 2. Representative immunohistochemical maspin protein stains showing four different TMA cores.
|
|
|
FIG A1. Data dictionary.
|
|
|
Fig 1. Total Body Mass vs. Leptin.
|
|
|
Supplemental Fig S1. Procedure for evaluation of the performance of the method using light and stable isotopically heavy-labeled λ Ig (SILuMAb).
|
|
|
Fig 1. Domain architecture of the NLRP1 inflammasome proteins.
|
|
![Fig. 1. Biodistribution of [225Ac]hu11B6.](https://library.mskcc.org/sparks/sparksimgs/4793/ProcNatAcSciUSA_Bicak.jpg)
